Publication details
Možnosti, limity a realita hodnocení protinádorové cílené terapie v ČR
| Title in English | Options, limits and reality for the assessment of cancer therapy in the Czech republic |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | targeted cancer therapy; cancer care assessment; personalized medicine |
| Description | Educational part of this work summarizes principles and problems associated with assessment of efficacy, safety and cost-effectiveness (CEA) of current targeted cancer therapy. Methodical survey highlights impact of data collected in clinical practice for relevant evaluation of this segment of personalized medicine. Based on survey of international literature, the review concludes that Czech health care system is still limited by a number of problems, namely: 1. there is not defined willingness to pay threshold; 2. lack of standardized methodology for the field of CEA; 3. there is none institutionally based, independent agency with capability to guarantee the field of CEA in a nationwide scale; 4. insufficient collaborative background of hospital information systems and consecutive problems with data accessibility. Regarding these drawbacks, the Czech Society for Oncology strives to build functional information platform in a form of specialized clinical registries, operating over the network of the Czech comprehensive cancer centres (CCCs). In the date of last validation necking (30. 10. 2010), the registries contained more than 9050 of fulfilled records on 12 targeted medications. Analysis of this representative data set proved well controlled usage of this cost demanding therapy in the CCCs as well as satisfying outcomes of the therapy. Most of the medications reached the same or even better survival parameters than in published randomized clinical trials. However, critical audit of epidemiological data revealed significant interregional heterogeneity in the accessibility of this therapy to cancer patients. |